|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.30 EUR | +0.74% |
|
-0.37% | -8.40% |
| 07-24 | European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading | MT |
| 07-16 | Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update | DJ |
| Market Cap | 20.52B 23.53B 19.15B 17.6B 33.03B 2,242B 33.82B 227B 88.68B 1,116B 88.26B 86.36B 3,845B | P/E 2026 * |
-18.5x | P/E 2027 * | -17.8x |
|---|---|---|---|---|---|
| Enterprise Value | 9.67B 11.09B 9.02B 8.29B 15.56B 1,057B 15.93B 107B 41.79B 526B 41.59B 40.69B 1,812B | EV / Sales 2026 * |
4.46x | EV / Sales 2027 * | 5.04x |
| Free-Float |
96.06% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioNTech SE
| 1 day | +0.74% | ||
| Current month | -8.40% | ||
| Current year | -8.40% |
| 3 years | 80.5 |  | 115.95 |
| 5 years | 80.5 | | 396.5 |
| 10 years | 11.5 | | 396.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Özlem Türeci
CTO | Chief Tech/Sci/R&D Officer | 59 | 2017-12-31 |
Ugur Sahin
CEO | Chief Executive Officer | 60 | 2008-06-01 |
| Director of Finance/CFO | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Helmut Jeggle
CHM | Chairman | 55 | 2008-06-01 |
| Director/Board Member | 69 | 2008-06-01 | |
| Director/Board Member | 65 | 2017-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -0.37% | - | - | 23.38B | |
| +0.47% | +2.03% | +51.54% | +70.84% | 55.01B | |
| +2.83% | +0.04% | +38.07% | +82.59% | 54.24B | |
| -0.97% | -5.06% | +1.35% | +383.00% | 22.57B | |
| +2.07% | +1.44% | +23.06% | -9.05% | 20.19B | |
| -2.15% | +0.78% | +24.67% | -31.03% | 17.86B | |
| -2.14% | -2.72% | +30.26% | +536.72% | 15.5B | |
| -3.14% | -8.09% | +160.68% | +292.18% | 14.2B | |
| -2.09% | -1.41% | +24.65% | +178.74% | 14.2B | |
| +1.50% | +0.02% | +85.91% | +166.11% | 12.42B | |
| Average | -0.29% | -0.25% | +48.91% | +185.57% | 25.13B | |
| Weighted average by Cap. | +0.36% | -0.07% | +44.23% | +147.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.17B 2.49B 2.02B 1.86B 3.49B 237B 3.57B 23.98B 9.37B 118B 9.33B 9.12B 406B | 2.23B 2.56B 2.08B 1.91B 3.59B 244B 3.68B 24.67B 9.64B 121B 9.6B 9.39B 418B |
| Net income | -1.04B -1.2B -975M -896M -1.68B -114B -1.72B -11.55B -4.51B -56.82B -4.49B -4.4B -196B | -1.16B -1.34B -1.09B -999M -1.88B -127B -1.92B -12.88B -5.03B -63.37B -5.01B -4.9B -218B |
| Net Debt | -10.85B -12.44B -10.13B -9.31B -17.47B -1,186B -17.88B -120B -46.9B -590B -46.67B -45.67B -2,034B | -9.28B -10.64B -8.66B -7.96B -14.94B -1,014B -15.3B -103B -40.12B -505B -39.93B -39.07B -1,739B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-29 | €81.30 | +0.74% | 1,974 |
| 26-07-28 | €80.70 | +0.56% | 3,412 |
| 26-07-27 | €80.25 | +2.16% | 2,046 |
| 26-07-24 | €78.55 | -2.78% | 5,741 |
| 26-07-23 | €80.80 | +0.44% | 4,282 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BNTX Stock
- 22UA Stock
Select your edition
All financial news and data tailored to specific country editions
